Perspective Therapeutics, Inc.
NYSE · Healthcare · Pharmaceutical Preparations · Seattle, WA
CATX chart
What traders are saying about $CATX
Latest postsPerspective Therapeutics, Inc. news
- Form 8K Perspective Therapeutics Inc For: 6 November By Investing.com
Investing.com Nigeria ·
- Perspective Therapeutics (CATX) Reports Interim Phase 1/2a Data on Targeted Alpha Therapy
GuruFocus ·
- Perspective Therapeutics, Inc. (CATX) stock price, news, quote and history
Yahoo Finance UK ·
- Perspective Therapeutics Reports Updated VMT01 Melanoma Trial Results
TipRanks ·
- Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026
Yahoo Finance ·
- Experimental melanoma treatment shrank tumors in 2 of 8 patients; one response remained after about 40 weeks.
Stock Titan ·
- Perspective Therapeutics Reports Bamzireotide Trial Data, Targets Phase 2 Meeting in 1Q 2027
TradingView ·
- Perspective Therapeutics (CATX) Stock Price, News & Analysis
MarketBeat ·
- Perspective Therapeutics (CATX) Shares New Phase 1/2a Data on Ta
GuruFocus ·
- Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
Yahoo Finance ·
- $CATX stock is down 10% today. Here's what we see in our data.
Quiver Quantitative ·
- Perspective Therapeutics (CATX) Stock Sees Fair Value Moves Lower As Analysts Weigh Lead 212 Risks
Yahoo Finance ·
Perspective Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$103.1M | -$79.3M | -$46.5M | -$10.8M |
| Diluted EPS | $-1.40 | $-1.23 | $-1.74 | – |
| Total assets (year end) | $267.0M | $341.1M | $97.9M | $58.1M |
| Cash and equivalents (year end) | $30.6M | $61.6M | $9.2M | $21.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Perspective Therapeutics, Inc.
- Ticker
- CATX (NYSE)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Seattle, WA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 728387
- Former names
- IsoRay, Inc., Isoray, Inc., CENTURY PARK PICTURES CORP
Frequently asked questions
What exchange is Perspective Therapeutics, Inc. listed on?
Perspective Therapeutics, Inc. trades on the NYSE under the ticker symbol CATX.
What industry is Perspective Therapeutics, Inc. in?
Perspective Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Perspective Therapeutics, Inc. headquartered?
Perspective Therapeutics, Inc.'s business address on file with the SEC is in Seattle, WA.
When does Perspective Therapeutics, Inc.'s fiscal year end?
Perspective Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Perspective Therapeutics, Inc. report?
Perspective Therapeutics, Inc. reported $5.9M in revenue for calendar year 2018, according to its SEC filings.